TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Justine Koenigsberg
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Kymera Therapeutics will report Q3 2025 financial results on November 4, 2025, and has recently presented preclinical data for two novel oral protein degrader drug candidates targeting immunological diseases.

Insights
JPMpM   positive

Shifting from Bitcoin skepticism to accepting Bitcoin as loan collateral


KYMR   positive

Company is advancing innovative drug development in targeted protein degradation, presenting promising preclinical data for two drug candidates (KT-579 and KT-621) with potential therapeutic applications in lupus, rheumatoid arthritis, and atopic conditions